跳至主要内容
临床试验/NCT01203982
NCT01203982已完成4 期

Effect of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment on Carotid Intima Media Thickness and Its Relation to Plaque Components of the Coronary Arteries in Patients With ST-Segment Elevation Acute Myocardial Infarction

Odense University Hospital1 个研究点 分布在 1 个国家目标入组 87 人开始时间: 2007年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
87
试验地点
1
主要终点
change from baseline in mean CIMT

研究概览

简要总结

The aim of this study was to measure the effect of moderate and intensive lipid-lowering treatment with rosuvastatin on the carotid intima-media thickness (CIMT) as a surrogate marker of cardiovascular risk.

详细描述

The aim of this study was to measure the effect of moderate (5mg) and intensive (40mg) lipid-lowering treatment with rosuvastatin on the carotid intima-media thickness as a surrogate marker of cardiovascular risk and to obtain whether CIMT correlated with the plaque components in coronary arteries evaluated with Intravascular Ultrasound Virtual Histology (IVUS-VH).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Investigator)

入排标准

年龄范围
18 Years 至 81 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • no prior treatment with statins and
  • a non significant lesion in one of the two non-culprit coronary arteries. -

排除标准

  • age below 18 or above 81 years,
  • unconscious patients,
  • serum creatinine > 176μmol/L,
  • total-cholesterol > 7.0 mmol/l,
  • hypothyroidism ((TSH > 1.5 x ULN (upper limit of normal)),
  • current liver disease (ALAT > 2 x ULN),
  • unexplained creatine kinase > 3 x ULN,
  • alcohol or drug abuse within the last five years,
  • prior myopathy or serious hypersensitivity reaction caused by statins,
  • women with childbearing potential who were not using chemical or mechanical contraception,
  • pregnant or breastfeeding women,
  • history of malignancy unless a disease-free period of more than five years was present,
  • patients with abnormal lung function test (LFT),
  • participation in another investigational drug study less than four weeks before enrolment in the present study,
  • treatment with cyclosporine or fibrates. -

研究组 & 干预措施

Rosuvastatin 5mg

Active Comparator

Rosuvastatin 5mg/day

干预措施: Rosuvastatin (Drug)

Rosuvastatin 40mg

Active Comparator

Rosuvastatin 40mg/day

干预措施: Rosuvastatin (Drug)

结局指标

主要结局

change from baseline in mean CIMT

时间窗: baseline, 6month, 12 month

Average of the far wall of common and bulbus carotid artery

次要结局

  • changes from baseline in max CIMT(baseline, 6month, 12 month)
  • change from baseline in mean common CIMT(baaseline, 6month 12 month)
  • change from baseline in max common CIMT(baseline, 6month 12month)
  • change from baseline in mean bulbus CIMT(Baseline, 6month 12 month)
  • change from baseline in max bulbus CIMT(baseline, 6month 12month)
  • change from baseline in lipid values(baseline, 6month 12month)
  • correlation between CIMT measurements and lipid values(Baseline, 6month 12 month)
  • correlation between CIMT measurements and plaque components evaluated by IVUS-VH(Baseline, 6month 12month)

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验